-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

Benzinga·10/06/2026 12:01:02
Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.